Business Use Case Analysis Statement of Value What is the benefits What are the key value statements for different action and communications Target Audience: Arriving toward and organization that wants to do authoring of clinical pathways Differentiate between those that want to do authoring verse those that are trying to consume authored artifacts
Out of Scope of Authoring Work group Why an institution would want to adopt or institute shareable pathways Bill: Are there studies about how pathways are instituted and used, and the implications of that. (ref: Look at oncology Pathways)
Examples: Clinical Pathways: Reducing Costs and Improving Quality Across a Network Impact of Electronically Accessible Pathways on Clinical Trial Enrollment at a Large Multisite Cancer Center Work What Success looks like? (6-12 mos) Why would someone want to be involved What is the path-How do I start, and what does the path look like? Best practices-how do I do this well ? What has been learned? Why should I want to be an author involved in BPM+? How does one take a 100+page PDF guideline and make it into a machine readable model that could be ingested into a system.” Taking the story, approach, tips, tricks, etc. so that other can do this. Either de novo or adapting existing content. This is authoring. New clinical societies Healthcare delivery orgs
Why would an organization choose this ? If we make the decision, how do we make it so? What does “doing it well” looks like: (e.g. Maturity Model, etc.)
Work Products to do this Artifact: Purpose: Audience: Thank you all! Next Mtgs: Authoring Clinical Steering Committee on Thursday, July 9, 12:00PM – 1:00pm EST Workgroup on Monday, June, 20 2:30pm – 4pm EST
Authoring Clinical Steering Committee on Thursday, Aug 12:00PM – 1:00pm EST Workgroup on Monday, August, 3 2:30pm – 4pm EST
|